A Study of Nystatin in the Prevention of Fungal Infections of the Mouth in Patients With AIDS or AIDS-Related Syndromes

Inclusion Criteria Concurrent Medication: Allowed: * Experimental drugs (IND drugs) which are targeted specifically against the AIDS virus or which stimulate the immune system. * Systemic or oral antibiotics. Patients must have AIDS or AIDS-related syndromes (HIV infection: * Group III or IV, CDC classification) and not have been treated for oral candidiasis during the past year. * Patients can be entered into the study who have: * Other oral lesions due to Kaposi's sarcoma, herpes zoster, and herpes simplex. * A positive or negative oral culture for Candida. * Must be able to follow instructions regarding the use of a pastille. Exclusion Criteria Co-existing Condition: Patients with the following are excluded: * Oral lesions diagnostic of oral candidiasis or systemic candidiasis. * Suspected or proven candidal esophagitis. Patients with the following are excluded: * Oral lesions diagnostic of oral candidiasis or systemic candidiasis. * Receiving any effective antifungal agent orally or intravenously within 72 hours of study entry. * Not expected to survive for at least 6 months. * Unable to voluntarily maintain a pastille in the buccal cavity for approximately 20 minutes twice a day. * Known hypersensitivity to nystatin. * Suspected or proven candidal esophagitis. Prior Medication: Excluded within 72 hours of study entry: * Any oral or intravenous antifungal agent.